Drugs Made In America Acquisition II Corp. DMII
are a blank check company incorporated in the Cayman Islands as an exempted company for the purpose of effecting a merger, share exchange,
asset acquisition, share purchase, recapitalization, reorganization or other similar business combination with one or more businesses.
We have neither engaged in any operations nor generated any revenue to date. Based on our business activities, the Company is a "shell
company" as defined under the Securities Exchange Act of 1934, as amended (the "Exchange Act") because we have no operations
Valuation FY2025 figures against the last close
Annual financial statements
Income statement
| Fiscal year | FY2025 | FY2024 |
|---|---|---|
| SG&A | $488.4K | — |
| Total operating expenses | $488.4K | — |
| Operating income | -$488.4K | — |
| Net income | $4.2M | — |
Balance sheet
| Fiscal year | FY2025 | FY2024 |
|---|---|---|
| Cash and equivalents | $223 | $17.0K |
| Total current assets | $26.0K | $59.6K |
| Total assets | $505.0M | $138.1K |
| Accounts payable | $99.4K | — |
| Total current liabilities | $300.9K | $254.8K |
| Total liabilities | $17.8M | $254.8K |
| Retained earnings | -$17.8M | -$151.7K |
| Total equity | -$17.8M | -$116.7K |
Cash flow
| Fiscal year | FY2025 | FY2024 |
|---|---|---|
| Operating cash flow | -$1.0M | — |
| Investing cash flow | -$500.0M | — |
| Financing cash flow | $501.0M | — |
Figures as tagged in each year's own filing, in US dollars. A year restated by a later filing shows the restated figure. Capital expenditure, dividends and buybacks are cash out, shown positive. A line the filer does not report is not listed. Latest from accession 0001213900-26-044055.
Plot the figures US dollars
- Revenue
- Gross profit
- Net income
| Fiscal year | FY2024 | FY2025 |
|---|---|---|
| Revenue | — | — |
| Gross profit | — | — |
| Net income | — | $4.2M |
Recent filings and events
- Material agreement signed The company entered an agreement outside the ordinary course of business - a large contract, a credit facility, a merger agreement. Item 1.01
- Annual report filed A new 10-K. The figures and the business description on this site come from it. Form 10-K
- Material agreement signed Item 1.01
- New debt or obligation The company has taken on debt or a comparable obligation. Item 2.03
- Material agreement signed Item 1.01
- New debt or obligation Item 2.03
- Other event The catch-all. The company chose to disclose something that fits no other item, so the content is whatever it says it is. Item 8.01
- Officer or director change Someone at the top arrived or left. The item covers everything from a board retirement to a chief executive being removed, and only the filing itself says which. Item 5.02
- Other event Item 8.01
- Officer or director change Item 5.02
- Other event Item 8.01
- Material agreement signed Item 1.01
Item numbers are Form 8-K's own, and a filing date is up to four business days after the thing it reports. The same feed across the whole market.
Others in SIC 6770
| Ticker | Company | Market cap | P/E | Revenue growth |
|---|---|---|---|---|
| IACO | Idea Acquisition Corp. | $437.9M | — | — |
| KRAQ | KRAKacquisition Corp | $430.8M | — | — |
| TACO | Berto Acquisition Corp. | $393.2M | 36.1x | — |
| ALDF | Aldel Financial II Inc. | $328.0M | — | — |
| ATII | Archimedes Tech SPAC Partners II Co. | $290.3M | — | — |
| FGII | FG Imperii Acquisition Corp. | $290.3M | — | — |
| SOUL | Soulpower Acquisition Corp. | $269.3M | — | — |
| DMAA | Drugs Made In America Acquisition Corp. | $264.0M | — | — |